QBIO
Q BioMed Inc.Company Information
- Company Name
- Q BioMed Inc.
- CIK
- CIK0001596062
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- QBIO: OTC
- Fiscal Year End
- November 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- QBIO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2018-07-12
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 38,500
Institutional Sentiment
- As of
- 2021-06-30
- Institutional shares owned
- 10,615
- Shares outstanding
- 26,283,700
- Ownership
- 0.04%
Earnings Market Reaction
- Filing date
- 2023-06-23
- Price on filing date
- —
- 1-month reaction
- 1185.71%
- 3-month reaction
- -71.43%
Balance Sheet
Values in millions ($)| Line item | 2023-02-28 | 2022-11-30 | 2022-08-31 | 2022-05-31 | 2022-02-28 | 2021-11-30 | 2021-08-31 | 2021-05-31 | 2021-02-28 | 2020-11-30 | 2020-08-31 | 2020-05-31 | 2020-02-29 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Series Preferred Stock | 0 | 1 | 0 | 0 | 0 | 1 | -0 | 0 | 1 | 0 | 0 | 1 | - | ||||||
| Convertible Series B Preferred Stock | 0 | 1 | -0 | -0 | 0 | 1 | -1 | 0 | 1 | 1 | 0 | 1 | - | ||||||
| Convertible Series C Preferred Stock | 100 | 100 | - | - | - | 100 | - | - | - | - | - | - | - | ||||||
Assets | |||||||||||||||||||
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | ||||||
Assets Current | |||||||||||||||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | - | ||||||
| Inventory Net | - | - | 0 | 0 | - | 0 | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Investments | 3 | 3 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Finite Lived Intangible Assets Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 3 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 1 | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||||
| Accounts Payable Current | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | ||||||
| Accrued Liabilities Current | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable Related Parties Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | |||||||||||||||||||
| Interest Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 10 | 8 | 8 | 8 | 6 | 5 | 4 | 3 | 3 | 2 | 2 | 2 | 4 | ||||||
| Notes Payable Related Parties Classified Current | - | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Debt Current | 4 | 4 | 4 | 3 | 3 | 3 | - | - | - | - | - | - | - | ||||||
| Derivative Liabilities Current | 0 | 0 | 0 | 1 | - | - | - | - | - | - | - | - | - | ||||||
Long Term Debt | |||||||||||||||||||
| Convertible Notes Payable | - | - | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 0 | - | 2 | ||||||
| Liabilities | 10 | 8 | 8 | 8 | 6 | 5 | 4 | 3 | 3 | 2 | 2 | 2 | 6 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | |||||||||||||||||||
| Stockholders Equity | -6 | -5 | -7 | -7 | -6 | -5 | -3 | -2 | -2 | -1 | 0 | 2 | -5 | ||||||
| Additional Paid In Capital | 57 | 56 | 56 | 55 | 54 | 53 | 53 | 52 | 50 | 48 | 45 | 45 | 43 | ||||||
| Retained Earnings Accumulated Deficit | -68 | -66 | -68 | -68 | -66 | -64 | -62 | -60 | -58 | -56 | -52 | -50 | -48 | ||||||
| Liabilities And Stockholders Equity | 3 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 133 | 84 | 57 | 39 | 31 | 29 | 28 | 27 | 26 | 24 | 23 | 23 | 21 | ||||||
| Shares Outstanding | 133 | 84 | 57 | 39 | 31 | 29 | 28 | 27 | 26 | 24 | 23 | 23 | 21 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialQ BioMed Inc. (QBIO) — SEC Financial Statements & Analysis
Q BioMed Inc. (QBIO) is a pharmaceutical preparations company, incorporated in NV. Q BioMed Inc. trades on OTC as: QBIO. Q BioMed Inc. (QBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2023-02-28, filed with the SEC on 2023-06-23. Based on that filing, On profitability, Q BioMed Inc. posts a gross margin of -6.02%, an operating margin of -1032.32%, a net margin of -920.75%, a Return on Equity (ROE) of 31.41%, and a Return on Assets (ROA) of -96.28%. Per share, it reports EPS of $-0.02, diluted EPS of $-0.02, free cash flow per share of $0.02, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -22.67% year-over-year, net income growth of -76.07% year-over-year, and EPS growth of -93.49% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-9.87M, a debt-to-equity ratio of -1.54x, a debt ratio of 2.86, an interest coverage ratio of -0.55x, free cash flow of $2.18M (TTM), and net debt of $4.03M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.02
- ROE TTM
- 31.41%
- ROA TTM
- -96.28%
- Debt To Equity
- -1.54x
- Free Cash Flow TTM
- $2.18M
- Net Revenue TTM Growth 1Y
- -22.67%
Data as of 2023-02-28 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Q BioMed Inc. in?
Q BioMed Inc. (QBIO) operates in the Pharmaceutical Preparations industry.
What exchange does QBIO trade on?
Q BioMed Inc. (QBIO) trades on the OTC.
Where is Q BioMed Inc. incorporated?
Q BioMed Inc. is incorporated in NV.
When was Q BioMed Inc. (QBIO)'s most recent SEC filing?
Q BioMed Inc. (QBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2023-02-28, filed with the SEC on 2023-06-23.
What is QBIO's EPS (earnings per share)?
Q BioMed Inc. (QBIO)'s trailing twelve month EPS is $-0.02 as of 2023-02-28.
What is QBIO's ROE (return on equity)?
Q BioMed Inc. (QBIO)'s trailing twelve month Return on Equity (ROE) is 31.41% as of 2023-02-28.
What is QBIO's ROA (return on assets)?
Q BioMed Inc. (QBIO)'s trailing twelve month Return on Assets (ROA) is -96.28% as of 2023-02-28.